GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Biosergen AB (OSTO:BIOSGN) » Definitions » Loans Receivable

Biosergen AB (OSTO:BIOSGN) Loans Receivable : kr0.00 Mil (As of Dec. 2024)


View and export this data going back to 2021. Start your Free Trial

What is Biosergen AB Loans Receivable?

Biosergen AB's Loans Receivable for the quarter that ended in Dec. 2024 was kr0.00 Mil.


Biosergen AB Loans Receivable Historical Data

The historical data trend for Biosergen AB's Loans Receivable can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Biosergen AB Loans Receivable Chart

Biosergen AB Annual Data
Trend Dec20 Dec21 Dec22 Dec23 Dec24
Loans Receivable
- - - - -

Biosergen AB Quarterly Data
Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24
Loans Receivable Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only - - - - -

Biosergen AB Loans Receivable Calculation

Loans Receivable are the funds that a company has lent but have not yet been repaid.


Biosergen AB Loans Receivable Related Terms

Thank you for viewing the detailed overview of Biosergen AB's Loans Receivable provided by GuruFocus.com. Please click on the following links to see related term pages.


Biosergen AB Business Description

Traded in Other Exchanges
N/A
Address
Fogdevreten 2, Solna, SWE, 17165
Biosergen AB is a biotech company developing innovative antifungal drugs based on latest biopharmaceutical research and development from laboratory facilities in Trondheim, Norway, and several other places worldwide. The company is developing BSG005, a potentially disruptive antifungal drug, which has demonstrated significant safety and potency advantages over competing antifungals.

Biosergen AB Headlines

No Headlines